Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar.

Esmée J GrobbeeVivian D de JongIlse C SchrieksMaarten E TushuizenAdriaan G HolleboomJean Claude TardifA Michael LincoffGregory G SchwartzManuel Castro CabezasDiederick E Grobbee

Published in: PloS one (2022)

This post-hoc analysis showed improvement of non-invasive tests of liver steatosis and fibrosis after starting dual PPAR-α/γ agonist treatment, adding to the evidence that this pathway has potential in non-alcoholic fatty liver disease treatment.

Keyphrases

insulin resistance
liver fibrosis
high fat diet
type diabetes
adipose tissue
metabolic syndrome
fatty acid
risk assessment
high fat diet induced
replacement therapy
human health